Martingale Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Martingale Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,007	Closed	-$293K	–	1015
2017 Q4	$293K	Sell	6,007 -3,293	-35%	-$167K	﹤0.01%	892
2017 Q3	$503K	Hold	9,300	–	–	0.01%	835
2017 Q2	$523K	Hold	9,300	–	–	0.01%	820
2017 Q1	$365K	Sell	9,300 -1,100	-11%	-$35K	0.01%	853
2016 Q4	$234K	Sell	10,400 -1,800	-15%	-$35.2K	﹤0.01%	915
2016 Q3	$278K	Buy	+12,200	New	+$286K	﹤0.01%	895

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Martingale Asset Management's PTLA Position: Q1 2018 in Review

Martingale Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2018, closing a stake of 6,007 shares — an estimated $293K sold.

Martingale Asset Management first reported a position in PTLA in Q3 2016 and held it in 6 quarters. The position peaked at $523K in Q2 2017. 180 funds tracked by Wall St. Rank hold PTLA as of Q1 2018.

Martingale Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Martingale Asset Management sold 6,007 Portola Pharmaceuticals, Inc. shares in Q1 2018, an estimated $293K.
Martingale Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2016 and held it in 6 quarters.
Martingale Asset Management's Portola Pharmaceuticals, Inc. position peaked at $523K in Q2 2017.
180 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2018.

Based on Martingale Asset Management's 13F filing for Q1 2018, filed 11 May 2018.